UNSPSC 51383701: Bumadizone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ATD81G944M, chemically known as 2-(2,3-diphenylcarbazoyl)hexansaeure but generally known as bumadizone, which bears US NIH Compound Identifier 19161. Bumadizone most often comes in base and calcium forms. European Medicines Agency schedules Bumadizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05968MIG.

UNSPSC 51383701 Bumadizone, a Commodity code, does not match the state and local procurement activity actually posted under this classification. The recent opportunities show state and local governments soliciting naloxone (opioid reversal), safe drug deactivation systems, generic pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs—none of which are bumadizone, an anti-inflammatory veterinary pharmaceutical. The code as tagged appears to be a data classification error or a mismatch between the UNSPSC taxonomy assignment and the underlying procurement scope.

Recent opportunities show health agencies and cooperative purchasing alliances (Seminole County, Florida; Texas Health and Human Services Commission; Minnesota Multistate Cooperative Purchasing Alliance) issuing IFB, RFI, and RFP notices for pharmaceutical products, delivery logistics, and supply-chain partnerships. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to evaluate vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. Minnesota's MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026, and contract performance weighted 75 percent on price competitiveness. The code shows little relevant recent activity aligned with its stated bumadizone scope; the opportunities posted under it address pharmaceutical procurement broadly, not the specific veterinary anti-inflammatory agent named in the UNSPSC code definition.